Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
18 January, 2022 15:56 IST
Venus Remedies receives nod under PLI Scheme
Source: IRIS | 09 Dec, 2021, 01.45PM
Rating: NAN / 5 stars.
Comments  |  Post Comment

Venus Remedies, a research based pharmaceutical company, has received approval from the Government of India under PLI 2.0 of the Production Linked Incentive (PLI) Scheme for manufacturers of pharmaceutical goods registered in India.

Venus is one of the 10 non-MSME pharmaceutical companies under category-C which have been granted approval under the PLI Scheme.

As per the scheme, the Company will be eligible for incentive for the financial years 2022-23 to 2027-28, subject to fulfillment of minimum investment criteria and based on incremental sales of eligible products as per the scheme guidelines.

Shares of the company gained Rs 27.65, or 5.88%, to trade at Rs 497.70.  The total volume of shares traded was 31,750 at the BSE (12.18 p.m, Thursday).

 Post Comment
Name Email
Security Code type    into this box
Related Articles
ICICI Bank: Leadership position to strengthen; Tech capabilities to drive sustainable growth - 18-Jan-2022 14:36
UltraTech Cement Q3FY22 Review - Outlook positive; Hold - 18-Jan-2022 14:23
VA Tech Wabag secures order worth USD 100 mn in Dubai - 17-Jan-2022 19:43
Glenmark Pharmaceuticals arm gets tentative approval for Regadenoson Injection - 17-Jan-2022 19:16
HDFC Bank Q3FY22 Review-Credit growth improved; Restructured assets at 1.37% vs 1.5% - 17-Jan-2022 17:25
HCL Technologies Q3FY22 Review- Margins to improve gradually - 17-Jan-2022 17:15
HDFC Bank: Earnings in line; Balance Sheet strengthens further - 17-Jan-2022 16:52
Renaissance Global partners with National Football League - 17-Jan-2022 11:26
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer